Gaby Sroczynski, MPH, Dr.PH
UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health, Health Services Research and HTA/ ONCOTYROL - Area 4, HTA and Bioinformatics
Department of Public Health and Health Technology Assessment
Eduard Wallnoefer Center I
Hall i.T./Innsbruck
Austria
6060
Papers:
1B-2
IMPROVING CERVICAL CANCER PRIMARY SCREENING AND DIAGNOSTIC FOLLOW-UP IN AUSTRIA – A DECISION-ANALYTIC BENEFIT-HARM ANALYSIS
1B-5
HEALTH-ECONOMIC EVALUATION OF HPV-BASED CERVICAL CANCER PRIMARY SCREENING COMPARED TO CYTOLOGY OR P16/KI-67 DUAL-STAINING – A DECISION-ANALYSIS FOR THE AUSTRIAN HEALTH CARE CONTEXT
2E-1
LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF DIFFERENT ANTIVIRAL TREATMENTS FOR CHRONIC GENOTYPE-1 HCV INFECTION IN GERMANY INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR
DIRECT ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 OR 4 IN FRANCE - COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR BY FIBROSIS SUBGROUP
THE BENEFIT-HARM BALANCE OF PROSTATE CANCER SCREENING IN MEN WITH AVERAGE AND ELEVATED FAMILIAL RISK – PREDICTIONS OF THE ONCOTYROL PROSTATE CANCER OUTCOME AND POLICY MODEL
BUDGET IMPACT ANALYSIS INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C IN FRANCE
COSTS OF FIRST-LINE TREATMENT FOR ELDERLY MULTIPLE MYELOMA PATIENTS WHO ARE NOT TRANSPLANT CANDIDATES IN THE SERBIAN HEALTH CARE SYSTEM